PATENT CLAIM ANALYSIS

Application Number: 16073897
Application Type: Utility
Filing Date: 2018-07
Publication Date: 2019-02
Patent Classification: ["544", "262000"]

Abstract:
Disclosed herein is a new route of synthesis and a new stable amorphous form of ibrutinib. Also disclosed are pharmaceutical compositions, oral dosage forms and the use of the amorphous ibrutinib in the treatment of mantle cell lymphoma or chronic lymphocytic leukemia.

Claim (Index 12):
A pharmaceutical composition comprising amorphous ibrutinib prepared by a process according to  claim 1 .

Metadata:
- Claim Count in Document: 2.0
- Percentile: 95.0
- Lexical Diversity: 1.32353
- Patent Class: 544.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['16073809', '15336418', '15853368', '15516285', '11455338']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7505863708446713
- 35 USC 102 Novelty (BERT): 0.4922944600185596
- Combined Prediction Score: 0.7247571797620601
- Mean Citation Score: 205.95125
- Max Citation Score: 240.31172
- Similarity Product: 176.35842845513343

Labels:
- Claim Label 101: 1
- Claim Label 102: 0
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 0
- Label 101 Adjusted: 1

Dataset: test